AstraZeneca Saphnelo Approved by Japanese Ministry of Health, Labor and Welfare
Developed by AstraZeneca (AZN), Saphnelo is a first-in-class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus. The approval by the Japanese Ministry of Health, Labor and Welfare (MHLW) was based on efficacy and safety data from the Saphnelo clinical . . .
This content is for paid subscribers.
Today’s Highlights September 28, 2021